Methods of treating by administering anti-kit antibodies

US10793639B2 · kind B2 · utility

Assignee

• Celldex Therapeutics, Inc. · US

Inventors

• Yaron R. Hadari · Harrison, US
• Elizabeth M Mandel-Bausch · Pleasant Prairie, US
• Susanne Radke · Hamden, US
• Joseph Schlessinger · New York, US
• Yoshihisa Suzuki · Akim Abodom, GH

Key dates

• Filing date: Dec 10, 2018
• Grant date: Oct 6, 2020
• Expiry date: Dec 10, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/912
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein.